Drug
Test Group Fcn 159
Test Group Fcn 159: highest development phase Phase 3, developed by Shanghai Fosun Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Shanghai Fosun Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Test group (Group A): FCN-159 8 mg, orally, once daily; NCT05913037 | Phase 3 | Neurofibromatosis 1 |
Latest
No recent events.
Follow Test Group Fcn 159 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.